Cyhoeddiad
2023
- Hulme, C. H. et al. 2023. The upscale manufacture of chondrocytes for allogeneic cartilage therapies. Tissue Engineering Part C Methods 29(9), pp. 424-437. (10.1089/ten.TEC.2023.0037)
2022
- Pepper, A. G. S. et al. 2022. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia 36, pp. 271-274. (10.1038/s41375-021-01322-1)
2021
- Norris, K. et al. 2021. High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders. Human Genetics 140, pp. 945-955. (10.1007/s00439-021-02257-4)
- Ashworth, I. et al. 2021. Telomere length in Cystic Fibrosis patients - are patients with CF ageing too quickly?. International Journal of Aging Research 4, article number: 90. (10.28933/ijoar-2021-06-2005)
2020
- Pepper, C., Norris, K. and Fegan, C. 2020. Clinical utility of telomere length measurements in cancer. Current Opinion in Genetics and Development 60, pp. 107-111. (10.1016/j.gde.2020.02.012)
2019
- Norris, K., Hillmen, P., Rawstron, A., Hills, R., Baird, D. M., Fegan, C. D. and Pepper, C. 2019. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia 33, pp. 1953-1963. (10.1038/s41375-019-0389-9)
2018
- Pilsworth, J. A. et al. 2018. TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology 31, pp. 1107-1115. (10.1038/s41379-018-0007-9)
- Cleal, K., Norris, K. and Baird, D. 2018. Telomere length dynamics and the evolution of cancer genome architecture. International Journal of Molecular Sciences 19(2), pp. 482-482. (10.3390/ijms19020482)
2014
- Lin, T. T. et al. 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167(2), pp. 214-223. (10.1111/bjh.13023)
2013
- Norris, K. 2013. An investigation into the chromatin structure of human telomeres. PhD Thesis, Cardiff University.
Articles
- Hulme, C. H. et al. 2023. The upscale manufacture of chondrocytes for allogeneic cartilage therapies. Tissue Engineering Part C Methods 29(9), pp. 424-437. (10.1089/ten.TEC.2023.0037)
- Pepper, A. G. S. et al. 2022. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia 36, pp. 271-274. (10.1038/s41375-021-01322-1)
- Norris, K. et al. 2021. High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders. Human Genetics 140, pp. 945-955. (10.1007/s00439-021-02257-4)
- Ashworth, I. et al. 2021. Telomere length in Cystic Fibrosis patients - are patients with CF ageing too quickly?. International Journal of Aging Research 4, article number: 90. (10.28933/ijoar-2021-06-2005)
- Pepper, C., Norris, K. and Fegan, C. 2020. Clinical utility of telomere length measurements in cancer. Current Opinion in Genetics and Development 60, pp. 107-111. (10.1016/j.gde.2020.02.012)
- Norris, K., Hillmen, P., Rawstron, A., Hills, R., Baird, D. M., Fegan, C. D. and Pepper, C. 2019. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia 33, pp. 1953-1963. (10.1038/s41375-019-0389-9)
- Pilsworth, J. A. et al. 2018. TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology 31, pp. 1107-1115. (10.1038/s41379-018-0007-9)
- Cleal, K., Norris, K. and Baird, D. 2018. Telomere length dynamics and the evolution of cancer genome architecture. International Journal of Molecular Sciences 19(2), pp. 482-482. (10.3390/ijms19020482)
- Lin, T. T. et al. 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167(2), pp. 214-223. (10.1111/bjh.13023)
Thesis
- Norris, K. 2013. An investigation into the chromatin structure of human telomeres. PhD Thesis, Cardiff University.